Reuters logo
BRIEF-Celyad reports first complete response in relapsed refractory AML patient in THINK trial ‍​
October 3, 2017 / 5:53 AM / in 14 days

BRIEF-Celyad reports first complete response in relapsed refractory AML patient in THINK trial ‍​

Oct 3 (Reuters) - CELYAD SA:

* REPORTS A FIRST COMPLETE RESPONSE IN A RELAPSED REFRACTORY AML PATIENT IN THE THINK TRIAL ‍​

* ONE AML PATIENT HAS ACHIEVED A MLFS AFTER ADMINISTRATION WITH CYAD-01 ATTHE H‍​

* FIRST EVER MORPHOLOGIC COMPLETE RESPONSE WITH GENE-ENGINEERED T CELLS WITHOUT PRIOR PRE-CONDITIONING CHEMOTHERAPY FOR A PATIENT WITH RELAPSED REFRACTORY AML‍​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below